Cargando...
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor...
Gardado en:
| Publicado en: | Mol Cancer |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5817870/ https://ncbi.nlm.nih.gov/pubmed/29455650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-018-0777-1 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|